Skip to main content
FDA releases draft guidance on eligibility criteria for cancer trials
3/14/2019

New FDA draft guidance suggests the inclusion of patients with HIV, hepatitis B and hepatitis C in cancer clinical trials based on predetermined conditions. The guidelines are being revised because too tightly defined criteria deter patient recruitment, which affects all other factors of a drug testing trial, including publication of data.

Full Story: